- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06822231
High-tech rehabilitační cesta pro akutní dospělé neuromuskulární onemocnění-FIT4Medrob-Acute MND Project (Fit4MR-AcMND)
Klinický protokol pro pragmatickou studii na high-tech rehabilitační cestě pro akutní neuromuskulární onemocnění dospělých (FIT4Medrob-akutní MND projekt)
The goal of this study is determine if a high-tech rehabilitation circuit is more effective than usual rehabilitation methods in improving functional outcome, particularly balance control, for patients with acute neuromuscolar diseases. The main question it aims to answer is:
Are high-tech rehabilitation interventions, including robotic systems, virtual reality, and stabilometric platforms, more effective than traditional rehabilitation methods in improving balance, motor function, fatigue levels, sarcopenia, cognitive engagement, and overall quality of life in patients with acute neuromuscular diseases (NMDs)? Researchers will compare a robotic treatment group, that consists in an high-tech rehabilitation, with a control group, that will receive the traditional rehabilitative treatment.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Objective: To evaluate the efficacy of a novel rehabilitation protocol integrating advanced technologies in the treatment of acute neuromuscular diseases (NMDs).
Background: NMDs affect muscle function and are directly controlled by the nervous system. Traditional rehabilitation often falls short in addressing the multifaceted needs of NMD patients. This gap underscores the necessity for innovative rehabilitation approaches that can significantly enhance the quality of life and optimize recovery outcomes following acute events.
Methods: The protocol integrates advanced technologies to address the rehabilitation needs of patients with acute NMDs. It utilizes robotic systems to ensure consistent and precise movement, virtual reality for immersive and engaging therapy, and stabilometric platforms to enhance balance training. The focus is on acute NMDs such as Guillain-Barré Syndrome (GBS), Critical illness myopathy (CIM) and polyneuropathy (CIP), either individually or in combination (CIP/CIM). The approach emphasizes rapid rehabilitation to maximize recovery outcomes.
Study Design: An interventional, randomized, superiority case-control study with a parallel assignment. The trial aims to compare the efficacy of high-tech rehabilitation methods against conventional treatments in improving patient outcomes.
Outcome Measures: To assess the improvement at least 10 points in balance measured using the Berg Balance Scale (BBS) from baseline to the end of the treatment period comparing the high-tech rehabilitation circuit with standard rehabilitation protocol.
Conclusion: This protocol seeks to determine if high-tech rehabilitation interventions can outperform traditional methods in acute NMDs. By doing so, it aims to potentially establish a new global standard for the care of patients with NMD care.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Christian Lunetta, MD
- Telefonní číslo: +39 0250725266
- E-mail: christian.lunetta@icsmaugeri.it
Studijní místa
-
-
-
Bari, Itálie, 70124
- Zatím nenabíráme
- Istituti Clinici Scientifici Maugeri
-
Kontakt:
- Pietro Fiore, MD
- Telefonní číslo: +39 0807814111
- E-mail: pietro.fiore@icsmaugeri.it
-
Vrchní vyšetřovatel:
- Pietro Fiore, MD
-
Genova, Itálie, 16132
- Zatím nenabíráme
- IRCCS Azienda Ospedaliera Universitaria San Martino - Genova
-
Kontakt:
- Angelo Schenone, MD
- Telefonní číslo: +39 010 3537065
- E-mail: aschenone@neurologia.unige.it
-
Vrchní vyšetřovatel:
- Angelo Schenone, MD
-
Milan, Itálie, 20138
- Nábor
- Istituti Clinici Scientifici Maugeri IRCCS, Milan Institute
-
Kontakt:
- Christian Lunetta
- Telefonní číslo: +390250725266
- E-mail: ilaria.consolo@icsmaugeri.it
-
Modena, Itálie, 41126
- Zatím nenabíráme
- Azienda Ospedaliero-Universitaria di Modena
-
Kontakt:
- Jessica Mandrioli, MD
- Telefonní číslo: +39 059 3961658
- E-mail: jmandrio@unimore.it
-
Vrchní vyšetřovatel:
- Jessica Mandrioli, MD
-
Montescano, Itálie, 27040
- Zatím nenabíráme
- Istituti Clinici Scientifici Maugeri
-
Kontakt:
- Cira Fundarò, MD
- Telefonní číslo: +39 0385247268
- E-mail: cira.fundaro@icsmaugeri.it
-
Vrchní vyšetřovatel:
- Cira Fundarò, MD
-
Pavia, Itálie, 27100
- Zatím nenabíráme
- Istituti Clinici Scientifici Maugeri
-
Kontakt:
- Antonio Nardone, MD
- Telefonní číslo: +39 0382592637
- E-mail: antonio.nardone@icsmaugeri.it
-
Vrchní vyšetřovatel:
- Antonio Nardone, MD
-
Roma, Itálie, 00135
- Zatím nenabíráme
- Fondazione Don Carlo Gnocchi Onlus
-
Kontakt:
- Irene Aprile, MD
- Telefonní číslo: +39 06 33086500
- E-mail: iaprile@dongnocchi.it
-
Vrchní vyšetřovatel:
- Irene Aprile, MD
-
Telese Terme, Itálie, 82037
- Zatím nenabíráme
- Istituti Clinici Scientifici Maugeri
-
Kontakt:
- Laura Marcuccio, MD
- Telefonní číslo: +39 0824909111
- E-mail: laura.marcuccio@icsmaugeri.it
-
Vrchní vyšetřovatel:
- Laura Marcuccio, MD
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Adults with ages ranging from 18 to 80 years.
- Patients with a confirmed diagnosis of acute/subacute neuromuscular diseases (e.g. GBS, CIM, CIP)
- Time of onset ranging from 15 to 30 days
- Patients with lower limb strength (Medical Research Council or MRC) >=2 in at least two of the flexor and extensor muscles of the following joints: hip, knee and ankle
- Possibility of obtaining informed consent
Exclusion Criteria:
- Patients with unstable medical conditions (e.g. severe cardiovascular diseases, such as "New York Heart Association" - NYHA=4, respiratory distress not compensated by ventilation) that could interfere, in the clinician's judgment, with their ability to safely participate in the study or to perform the assessments related to the protocol.
- Patients currently participating in other clinical trials that could interfere with this study.
- Pregnant or breastfeeding women.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Jiný
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Robotic treatment group
In this arm, patients will be divided into 3 treatment types based on their Berg Balance Scale (BBS) score at the time of randomization. Phase 1 (BBS <= 20) involves treatment with a robotic verticalization system (ERIGO) and action observation training with a virtual reality device. Phase 2 (21 < BBS < 40) involves treatment with a robotic verticalization system (ERIGO), action observation training with a virtual reality device, and proprioceptive exercises on robotic platforms (e.g. GEA MASTER or PROKIN Technobody). Phase 3 (BBS >= 41) involves motor and cognitive exercises using virtual reality device, proprioceptive exercises on robotic platforms (e.g. GEA MASTER or PROKIN Technobody), and aerobic exercises on a robotic treadmill (e.g. Walkerview Technobody). |
Robotic Verticalization System (e.g., Erigo): Assists in regaining upright posture and mobility. Virtual Reality (e.g., VRRS Evo): Provides an engaging and immersive environment for cognitive and motor exercises. Stabilometric Platform (e.g., Gea Master or Prokin Technobody): Used for balance and postural control training. Treadmill System (e.g., Walkerview Technobody): Used for aerobic exercises with gait analysis and feedback |
|
Jiný: Control group
The patients will receive the traditional rehabilitative treatment according to the good clinical practice according to the Diagnostic, Therapeutic and Care Pathways of each center involved |
Traditional rehabilitative treatment |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change from baseline in Berg Balance Scale
Časové okno: At the end of treatment at day 60
|
Improvement in balance measured by the Berg Balance Scale (BBS), with a target improvement of at least 10 points from baseline to the end of the treatment period. BBS is used to objectively determine a patient's ability (or inability) to safely balance during a series of 14 tasks; each task ranks from 0 to 4, with a total score of 56. Higher score indicates the higher level of function. |
At the end of treatment at day 60
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change from baseline in Modified Barthel Index
Časové okno: At day 15, at day 30, at day 45, at day 60
|
Modified Barthel Index (MBI). The MBI is an adaptation of the original Barthel Index, designed to assess a patient's ability to perform activities of daily living (ADLs) and their level of independence. The MBI evaluates ten specific functions: Feeding, Bathing, Grooming, Dressing, Bowel control, Bladder control, Toileting, Transfers (e.g., bed to chair), Mobility (e.g., walking or wheelchair use), Stair climbing. Each item is scored on a 5-level ordinal scale. Interpretation: 0-20, Total dependency; 21-60, Severe dependency; 61-90, Moderate dependency; 91-99, Slight dependency; 100, Independence |
At day 15, at day 30, at day 45, at day 60
|
|
Change from baseline in Trunk Control Test
Časové okno: At day 15, at day 30, at day 45, at day 60
|
Trunk Control Test (TCT) for non-ambulatory patients. The TCT is a clinical assessment tool used to evaluate trunk movement control in patients, particularly those who have suffered a stroke or other neurological disorders. The TCT measures four specific movements: 1) Rolling to the weak side: The patient rolls from a supine position to their weaker side; 2) Rolling to the strong side: The patient rolls from a supine position to their stronger side; 3) Balance in a sitting position: The patient sits on the edge of a bed or table without support for at least 30 seconds; 4) Sitting up from lying down: The patient moves from a lying to a sitting position. Each movement is scored on a scale from 0 to 25, with a total possible score of 100. Higher scores indicate better trunk control (Collin & Wade 1990) |
At day 15, at day 30, at day 45, at day 60
|
|
Change from baseline in 2-Minute Walk Test
Časové okno: At day 15, at day 30, at day 45, at day 60
|
2-Minute Walk Test (2MWT) for ambulatory patients. The Two-Minute Walk Test (2MWT) is a simple and quick assessment used to measure a person's walking endurance and functional mobility. It is based on the measurement of the distance that a person can walk in two minutes. The individual is instructed to walk as far as possible in two minutes, typically along a marked course. Assistive devices can be used if needed, but should be kept consistent across tests. The total distance walked in meters or feet is recorded |
At day 15, at day 30, at day 45, at day 60
|
|
Change from baseline in Modified Erasmus GBS Outcome Score
Časové okno: At the end of treatment at day 60
|
Modified Erasmus GBS Outcome Score (mEGOS) for Guillain-Barrè Syndrome patients: is a clinical prediction model used to estimate the likelihood of a patient with GBS being unable to walk independently six months after disease onset. This score is calculated based on three key factors: 1) Age at onset of neurological symptoms; 2) Preceding diarrhea before the onset of symptoms; 3) Severity of muscle weakness, assessed using the Medical Research Council sum score. The mEGOS provides a score ranging from 0 to 12, with higher scores indicating a higher risk of walking inability |
At the end of treatment at day 60
|
|
Change from baseline in Handgrip strenght test
Časové okno: At day 15, at day 30, at day 45, at day 60
|
Maximal isometric handgrip strength for both right and left hands will be measured using a digital handgrip dynamometer in units of kg/f in the standardized position recommended by the American Society of Hand Therapists, that is, sitting in a chair with a 90° backrest and 90° elbow flexion of the hand to be evaluated. Each participant exerted three trials of 3 s of maximal isometric handgrip strength alternatively for the right and left hands, with a rest period of 180 s between trials and considering the best performance of the three trials for statistical analysis |
At day 15, at day 30, at day 45, at day 60
|
|
Change from baseline in Isometric muscles strenght
Časové okno: At day 15, at day 30, at day 45, at day 60
|
Isometric muscle strength, measured in kg, was assessed using a manual hand-held dynamometer (HHD) at the deltoid, biceps brachii, triceps brachii, wrist flexor, and wrist extensor for the upper limbs bilaterally; thigh flexor, knee extension, knee flexion, dorsiflexion, and plantarflexion for the lower limbs bilaterally |
At day 15, at day 30, at day 45, at day 60
|
|
Change from baseline in Numeric Rating Scale
Časové okno: At day 30 and day 60
|
Measured using the Numeric Rating Scale (NRS). The NRS for fatigue is a simple and widely used tool to assess the intensity of fatigue. It helps patients communicate their fatigue levels to healthcare providers effectively. The NRS typically uses an 11-point scale ranging from 0 (no fatigue) to 10 ("the worst fatigue imaginable"). Patients are asked to rate their fatigue by selecting a number that best represents their pain intensity at that moment. |
At day 30 and day 60
|
|
Change from baseline in 12-Short Form-12 Survey
Časové okno: At day 30 and day 60
|
It will be used the 12-Item Short Form Survey (SF-12). The SF-12 is a self-reported questionnaire designed to measure health-related quality of life. It is a shortened version of the SF-36, created to reduce the burden on respondents while still providing reliable and valid results. The SF-12 covers eight health domains: Physical functioning; Role-physical (limitations due to physical health problems); Bodily pain; General health; Vitality (energy and fatigue); Social functioning; Role-emotional (limitations due to emotional problems); Mental health (psychological distress and well-being). The survey produces two summary scores: Physical Component Summary (PCS) and Mental Component Summary (MCS). These scores are norm-based, with a mean of 50 and a standard deviation of 10. Scores above 50 indicate better-than-average health-related quality of life, while scores below 50 suggest below-average health |
At day 30 and day 60
|
|
Change from baseline in Technology Assisted Rehabilitation Patient Perception Questionnaire
Časové okno: At day 30, at day 60
|
To assess the patient perception of the technology assisted rehabilitation using the Technology Assisted Rehabilitation Patient Perception Questionnaire (TARPP-Q). The TARPP-Q consists of 10 questions with multiple choice answers, totalling 29 items. The Questionnaire assesses patients' personal experiences and perceptions of technology assisted rehabilitation, including aspects like usability, positive attitude, hindrance perception, and distress. |
At day 30, at day 60
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change from baseline in Insulin Growth Factor 1 and free Insulin Growth Factor 1
Časové okno: At day 15, at day 30, at day 60
|
Will be measured these biomarkers in order to assess the levels changes during the treatment. Serum level will be measured in nanogram/milliliter |
At day 15, at day 30, at day 60
|
|
Change from baseline in Neurofilament-Light chain
Časové okno: At day 15, at day 30, at day 60
|
Will be measured this biomarker in order to assess the levels changes during the treatment. Plasma level will be measured in picogram/milliliter. |
At day 15, at day 30, at day 60
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Postinfekční poruchy
- Nemoci nervového systému
- Patologické procesy
- Neuromuskulární onemocnění
- Chronické onemocnění
- Atributy nemoci
- Autoimunitní onemocnění
- Onemocnění imunitního systému
- Onemocnění periferního nervového systému
- Autoimunitní onemocnění nervového systému
- Demyelinizační onemocnění
- Polyneuropatie
- Polyradikuloneuropatie
- Patologické stavy, příznaky a symptomy
- Guillain-Barre syndrom
- Terapeutika
- Péče o pacienty
- Zdravotní služby
- Zdravotnická zařízení pracovní síla a služby
- Následná péče
- Kontinuita péče o pacienty
- Rehabilitace
Další identifikační čísla studie
- 2024_0053110
- PNC0000007 (Jiné číslo grantu/financování: Ministry of University and Research)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .